Menu Search
Equities

Centrum Medyczne Enel Med SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ENE:WSE

Centrum Medyczne Enel Med SA

Actions
Health CareHealth Care Providers
  • Price (PLN)22.40
  • Today's Change0.80 / 3.70%
  • Shares traded2.25k
  • 1 Year change+12.00%
  • Beta0.2775
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Centrum Medyczne Enel Med SA is a Poland-based company that provides medical services. The Company is the parent company of the ENEL-MED Capital Group. It offers medical services on the Polish healthcare market for both private patients and those using services within the National Health Fund. The Company provides medical services including: basic and specialist outpatient care, including rehabilitation and outpatient procedures, dental care, including implantology, prosthetics and orthodontics, diagnostic imaging tests, hospitalization, including procedures and surgeries in selected specializations in the form of elective surgeries, out-of-home medicine and interventional home visits as well as aesthetic medicine.

  • Revenue in PLN (TTM)820.59m
  • Net income in PLN10.40m
  • Incorporated2007
  • Employees1.20k
  • Location
    Centrum Medyczne Enel Med SAul. Slominskiego 19 lok. 524WARSZAWA 00-195PolandPOL
  • Phone+48 224317701
  • Fax+48 224317702
  • Websitehttps://www.enel.pl/
More ▼

Institutional shareholders

22.88%Per cent of shares held by top holders
HolderShares% Held
Generali PTE SAas of 31 Dec 20244.71m16.67%
Allianz Polska PTE SAas of 31 Dec 20241.76m6.21%
PTE PZU SAas of 30 Jun 20250.000.00%
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.